Analysis of prognostic factors in peripheral T-cell lymphoma: prognostic value of serum albumin and mediastinal lymphadenopathy.
We evaluated multiple patient characteristics for their prognostic significance in patients with peripheral T-cell lymphoma (angioimmunoblastic T-cell lymphoma [AITL; n = 31] and peripheral T-cell lymphoma, not otherwise unspecified [PTCL-NOS; n = 37]). Five-year overall survival (OS) rates in AITL and PTCL-NOS were 49% and 45%, respectively (p = 0.89). Cox proportional hazard model revealed that male sex, hemoglobin <10.0 g/dL and performance status (PS) > or =2 were independently associated with shorter OS in AITL. In patients with PTCL-NOS, low albumin, PS > or = 2, and mediastinal lymphadenopathy were independently associated with worse OS. When analysis in PTCL-NOS was performed incorporating Prognostic Index for PTCLu (PIT), low albumin and mediastinal lymphadenopathy were still both prognostic for OS. Three-year progression free survival (PFS) rates in AITL and PTCL-NOS were 49% and 47%, respectively (p = 0.578). None of the parameters was significantly associated with shorter PFS in AITL. In patients with PTCL-NOS, PS > or = 2 and mediastinal lymphadenopathy were independently associated with shorter PFS. The result is in keeping with previous large scale studies. Besides, we showed the potential prognostic importance of albumin and mediastinal lymphadenopathy in patients with PTCL-NOS.
Chihara
Dai
D
Department of Hematology and Cell Therapy, Aichi Cancer Center Hospital, Nagoya, Japan.
Oki
Yasuhiro
Y
Ine
Shouji
S
Yamamoto
Kazuhito
K
Kato
Harumi
H
Taji
Hirofumi
H
Kagami
Yoshitoyo
Y
Yatabe
Yasushi
Y
Nakamura
Shigeo
S
Morishima
Yasuo
Y
D000971:Antineoplastic Combined Chemotherapy Protocols / Q000627:therapeutic use*; D003131:Combined Modality Therapy; D003520:Cyclophosphamide / Q000008:administration & dosage; D018572:Disease-Free Survival; D004317:Doxorubicin / Q000008:administration & dosage; D005260:Female; D006801:Humans; D008206:Lymphatic Diseases / Q000175:diagnosis; D016411:Lymphoma, T-Cell, Peripheral / Q000097:blood / Q000473:pathology / Q000628:therapy*; D008297:Male; D008477:Mediastinal Diseases / Q000175:diagnosis; D008875:Middle Aged; D011241:Prednisone / Q000008:administration & dosage; D011379:Prognosis; D016016:Proportional Hazards Models; D012709:Serum Albumin / Q000032:analysis; D012737:Sex Factors; D033581:Stem Cell Transplantation / Q000379:methods*; D014182:Transplantation, Autologous; D016896:Treatment Outcome; D014750:Vincristine / Q000008:administration & dosage
D012709:Serum Albumin; D014750:Vincristine; D004317:Doxorubicin; D003520:Cyclophosphamide; D011241:Prednisone